These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23040224)

  • 41. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.
    Meirovitz A; Murdoch-Kinch CA; Schipper M; Pan C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):445-53. PubMed ID: 16839705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of long term (10-years+) dysphagia and trismus in patients treated with concurrent chemo-radiotherapy for advanced head and neck cancer.
    Kraaijenga SA; Oskam IM; van der Molen L; Hamming-Vrieze O; Hilgers FJ; van den Brekel MW
    Oral Oncol; 2015 Aug; 51(8):787-94. PubMed ID: 26027851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry.
    Kamal M; Mohamed ASR; Volpe S; Zaveri J; Barrow MP; Gunn GB; Lai SY; Ferrarotto R; Lewin JS; Rosenthal DI; Jethanandani A; Meheissen MAM; Mulder SL; Cardenas CE; Fuller CD; Hutcheson KA;
    Radiother Oncol; 2018 Sep; 128(3):442-451. PubMed ID: 29961581
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Practical considerations in reducing swallowing dysfunction following concurrent chemoradiotherapy with intensity-modulated radiotherapy for head and neck cancer.
    Batth SS; Caudell JJ; Chen AM
    Head Neck; 2014 Feb; 36(2):291-8. PubMed ID: 23508721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of selective neck dissection on chronic dysphagia after chemo-intensity-modulated radiotherapy for oropharyngeal carcinoma.
    Hutcheson KA; Abualsamh AR; Sosa A; Weber RS; Beadle BM; Sturgis EM; Lewin JS
    Head Neck; 2016 Jun; 38(6):886-93. PubMed ID: 26339764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes.
    Gensheimer MF; Liao JJ; Garden AS; Laramore GE; Parvathaneni U
    Radiat Oncol; 2014 Nov; 9():255. PubMed ID: 25424729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Study of Dysphagia-optimized Intensity Modulated Radiotherapy (Do-IMRT) and Standard Intensity Modulated Radiotherapy (S-IMRT) and Its Clinical Correlation in Head and Neck Cancer Patients.
    Batham S; Gupta S; Ghosh A; Gupta IJ; Johny D; Srivastava S; Singh N; Bhatt M; Gupta R; Bhosale VV; Negi M
    Asian Pac J Cancer Prev; 2023 Nov; 24(11):3697-3704. PubMed ID: 38019227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT±concurrent chemotherapy.
    Moroney LB; Helios J; Ward EC; Crombie J; Wockner LF; Burns CL; Spurgin AL; Blake C; Kenny L; Hughes BG
    Oral Oncol; 2017 Jan; 64():1-8. PubMed ID: 28024718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dysphagia. Impact on quality of life after radio(chemo)therapy of head and neck cancer.
    Maurer J; Hipp M; Schäfer C; Kölbl O
    Strahlenther Onkol; 2011 Nov; 187(11):744-9. PubMed ID: 22037655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
    Nutting C; Finneran L; Roe J; Sydenham MA; Beasley M; Bhide S; Boon C; Cook A; De Winton E; Emson M; Foran B; Frogley R; Petkar I; Pettit L; Rooney K; Roques T; Srinivasan D; Tyler J; Hall E;
    Lancet Oncol; 2023 Aug; 24(8):868-880. PubMed ID: 37423227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects: Implications for Clinical Trial Design.
    Ward MC; Ross RB; Koyfman SA; Lorenz R; Lamarre ED; Scharpf J; Burkey BB; Joshi NP; Woody NM; Prendes B; Houston N; Reddy CA; Greskovich JF; Adelstein DJ
    JAMA Otolaryngol Head Neck Surg; 2016 Dec; 142(12):1164-1170. PubMed ID: 27438230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dysphagia and trismus after concomitant chemo-Intensity-Modulated Radiation Therapy (chemo-IMRT) in advanced head and neck cancer; dose-effect relationships for swallowing and mastication structures.
    van der Molen L; Heemsbergen WD; de Jong R; van Rossum MA; Smeele LE; Rasch CR; Hilgers FJ
    Radiother Oncol; 2013 Mar; 106(3):364-9. PubMed ID: 23540551
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
    Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancer.
    Kohler RE; Sheets NC; Wheeler SB; Nutting C; Hall E; Chera BS
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):683-9. PubMed ID: 24138916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quality-of-life scores compared to objective measures of swallowing after oropharyngeal chemoradiation.
    Kendall KA; Kosek SR; Tanner K
    Laryngoscope; 2014 Mar; 124(3):682-7. PubMed ID: 23929736
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of minor salivary glands in developing patient-rated xerostomia and sticky saliva during day and night.
    Beetz I; Schilstra C; Visink A; van der Schaaf A; Bijl HP; van der Laan BF; Steenbakkers RJ; Langendijk JA
    Radiother Oncol; 2013 Nov; 109(2):311-6. PubMed ID: 23953752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.